Standardized Measurement of Femoral Artery Depth by Computed Tomography to Predict Vascular Complications After Transcatheter Aortic Valve Implantation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 10 11 2020
revised: 22 12 2020
accepted: 29 12 2020
pubmed: 19 1 2021
medline: 17 4 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

Vascular complications (VCs) are difficult to predict and remain an important issue after transfemoral (TF) transcatheter aortic valve implantation (TAVI) although their incidence has decreased with size reduction of introducers. We aimed to evaluate a standardized measurement of femoral artery depth (FAD) using computed tomography (CT) to predict VCs after TAVI. We performed a retrospective study of 679 TF TAVI patients. We evaluated a standardized CT method to measure FAD immediately above the bifurcation. Sheath-to-femoral-artery ratio (SFAR), calcification, and tortuosity were also evaluated. VCs were defined by the Valve Academic Research Consortium (VARC)-2. Receiver operating characteristic (ROC) curves were used to predict major VCs and the need for a stent-graft. The median values of FAD and SFAR were 49.0 (36.2 to 66.7) mm and 0.95 (0.81 to 1.18), respectively. Major VCs occurred in 37 (5.4%) patients and a stent-graft was required in 49 (7.1%) patients. FAD predicted the need for a stent-graft [0.61 (0.51 to 0.70), p = 0.04] but not major VCs [0.52 (0.40 to 0.63), p = 0.76]. In contrast, SFAR did not predict the need for a stent-graft [0.53 (0.43 to 0.62), p = 0.61] but predicted major VCs [0.70 (0.58 to 0.81), p = 0.001]. Calcification and tortuosity predicted neither major VCs nor the need for a stent-graft. In conclusion, the results of our study suggest that CT measurements of FAD and SFAR provide additional information to predict major VCs and the need for a femoral stent-graft after TF TAVI.

Identifiants

pubmed: 33460601
pii: S0002-9149(21)00047-3
doi: 10.1016/j.amjcard.2020.12.089
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-127

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

DECLARATION OF COMPETING INTEREST Eric Durand has received lecture fees from Edwards Lifesciences.

Auteurs

Eric Durand (E)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France. Electronic address: eric.durand@chu-rouen.fr.

Maryline Penso (M)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Thibault Hemery (T)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Thomas Levesque (T)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Gustavo Moles (G)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Christophe Tron (C)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Najime Bouhzam (N)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Nicolas Bettinger (N)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Stephanie Wong (S)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Radiology, FHU CARNAVAL, F-76000 Rouen, France.

Jean-Nicolas Dacher (JN)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Radiology, FHU CARNAVAL, F-76000 Rouen, France.

Hélène Eltchaninoff (H)

Normandie Univ, UNIROUEN, Inserm U1096, CHU Rouen, Department of Cardiology, FHU CARNAVAL, F-76000 Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH